Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAP2K4 | P45985 | 8/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14979247 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1NTRK1KDM4ELMNA | |
| SCHEMBL13172609 | 0.84 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1MAP2K4GSK3B | |
| SCHEMBL1989361 | 0.81 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1KDM4ELMNAPKM | |
| SCHEMBL14979221 | 0.80 | MAP2K4 (0.54) | MAP2K4MAPK1MAPK6GSK3BLMNA | |
| SCHEMBL20248058 | 0.78 | KDM4E (0.66) | SMN1; SMN2ALDH1A1MAP2K4MAPK1MAPK6 | |
| SCHEMBL23914767 | 0.78 | MAP2K4 (0.51) | SMN1; SMN2MAP2K4MAPK1MAPK6GSK3B | |
| SCHEMBL5677771 | 0.77 | MAP2K4 (0.51) | MAP2K4MAPK1MAPK6GSK3B | |
| SCHEMBL119757 | 0.76 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1GSK3BCYP1A2KDM4E | |
| SCHEMBL11753413 | 0.76 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1GSK3BNTRK1KDM4E | |
| SCHEMBL3394416 | 0.75 | PTGS1 (0.44) | ALDH1A1KDM4ELMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2781508-B9 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| EP-2781508-B1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO LTD (CN) | 2018-12-12 | — | — | EP | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233098-B2 | Nitrogen-containing fused ring compounds as CRTH2 antagonists | KBP BIOSCIENCES CO., LTD. (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | KBP BIOSCIENCES CO., LTD. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2781508-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | KBP Biosciences Co., Ltd. (CN) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013071880-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS | 山东亨利医药科技有限责任公司 (CN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303186-A1 | NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS | HRH2, HRH1, NR3C2 | SMN1; SMN2 1546/4885ALDH1A1 3981/4885MAP2K4 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.